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A circulating inhibitor of the RBC membrane calcium pump in chronic
renal failure. A humoral inhibitor of the membrane calcium pump was
studied in plasma from 28 normal controls, 33 patients receiving
long-term hemodialysis, and 26 with chronic renal failure (CRF; creat-
mine clearance range was 6 to 97 mI/mm). Calcium pump activity was
measured as the rate of Sr2 effiux in normal erythrocytes (RBCs)
loaded with Sr2 (a substitute of Ca2 in the calcium pump). Plasma,
and plasma ultraffitrates from hemodialysis patients strongly inhibited
calcium pump activity compared with controls without plasma (36 18
vs. 25 12 , %LNHIBITION/CONTROL, P < 0.05). Inhibition
markedly decreased with acute hemodialysis (16 12 vs. 5 14,
%INHIBITION/NORMAL PLASMA, N = 15, P < 0.001). In CRF,
degree of inhibition correlated with the serum creatinine concentration
(r = 0.75, P < 0.001). A kinetic study showed that plasma decreased the
maximal rate of the Ca2 pumps (Vmax) without affecting the apparent
affinity for internal cations (K5r). Moreover, the plasma inhibitory
factor had a low molecular weight, and was dialyzable and heat stable.
ln conclusion, we found evidence for an RBC membrane calcium pump
inhibitor in uremic plasma, which correlates with the degree of renal
insufficiency. Possibly, it may increase calcium content in RBCs and
other cells and could thus be related to uremic toxicity and/or hyper-
tension.
Increased intracellular Na and a defective Na -K-ATPase
activity in erythrocytes (RBCs) of uremic patients were first
described by Welt, Sachs and Manus in 1964 [1]. These findings
were subsequently confirmed in several [2, 3], but not all [4—61
laboratories. Subsequently, it was shown that the defective
Na-K-ATPase activity can be acquired by normal RBCs
upon exposure to uremic sera [7, 81. Similar endogenous
Na-K-ATPase inhibitory factors were found in plasma from
normal [91 or hypertensive subjects [10], and volume-expanded
animals [11, reviewed in 12]. Recently, increased levels of such
endogenous "digitalis-like factors" (EDLF) were reported in
azotemic patients [13]. However, the precise role of these
factors in chronic renal failure (CRF), has not been established
[3, 5, 13].
In contrast with the numerous studies of Na transport in
uremia, there is limited information concerning intracellular
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free Ca2 and transmembrane Ca2 transport in uremia [14—161.
This is striking, since maintenance of a low cell Ca2 level is
essential to cell survival [17, 181. Indeed, RBC survival is
reduced in patients with advanced renal failure [19, 20], and it
was suggested that this is related to extracorpuscular factors,
such as PTH-induced Ca2 entry into the cell [16]. Recently,
Gafter et al [14] found an increased total RBC Ca2 content and
decreased Ca2 vATPase activity in RBC membrane ghosts
from patients with end-stage renal disease. The presence of a
circulating inhibitory factor was suggested by the recovery of
normal Ca2 -ATPase activity after hemodialysis and by the
inhibition of membrane Ca2-ATPase by pre-incubation with
ureniic plasma [14].
Lindner, Kenny and Meacham [211 recently described a
humoral factor which increases intracellular free calcium con-
tent in platelets in plasma from essential hypertensive patients.
Moreover, a circulating inhibitor of the Ca2-ATPase may be
causally related to RBCs reduced survival, and to widespread
cellular toxicity and/or hypertension in CRF, through the in-
crease in intracellular levels of free Ca2t Finally, most of the
interacting regions of the Ca2-ATPase are intracellular [221. A
circulating factor, however, would have access to the Ca2-
ATPase only by interacting initially at the external side of the
cell. Broken RBC membranes or RBC ghosts may not be
suitable to investigate the presence of a circulating factor. For
these reasons, we decided to further investigate the direct effect
of uremic plasma upon Ca2 pump activity in intact RBCs. We
confirmed the presence of a circulating Ca2 pump inhibitor in
uremic plasma, which was directly correlated to the decrease in
renal function. The activity of this Ca2 transport inhibitor was
markedly reduced by acute hemodialysis, while it appeared in
the ultrafiltrate across the dialysis membrane. The factor was
initially characterized as a heat-stable molecule, smaller than
3,000 molecular weight.
Methods
Subject groups
Normotensive controls. Plasma samples were obtained from
28 unselected controls of either sex (15 women and 13 men)
with an average age 38 11 years, whose sitting blood pressure
was < 140/90 mm Hg.
Patients with a chronic renal insufficiency. I'wenty-six pa-
tients (10 women and 16 men, aged 57 15 years), with a wide
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spectrum of renal dysfunction, whose serum creatinine concen-
tration (mo1Iliter) ranged from 62 to 916 and averaged 228
216 imollliter comprised this group.
Maintenance hemodialysis patients. A group of 33 patients
(16 men and 17 women, average age 45 13 years) had received
maintenance hemodialysis for periods of one to 81 month(s)
duration. All were dialyzed three times weekly, usually with
cellulose acetate membranes, and rarely with cuprophane or
polysulphone high permeability membranes. A history of pre-
vious hypertension was recorded in about 70% of the cases, and
these were usually treated with a variety of antihypertensive
drugs, including calcium blockers in nine cases. In the patient
groups, blood pressure was measured by sphygmomanometry,
using an average of three readings one minute apart. Weight
losses, volume of ultrafiltration, and blood pressure changes
during hemodialysis were recorded on the same date that
samples were drawn for testing of plasma factors. In 15 of the 33
patients, a second blood sample was obtained for comparison at
the end of dialysis. Finally, serum parathyroid hormone levels
(intact 1-84 PTH, measured by radioimmunoassay at Nickols
Laboratory) were recorded from recent data for the dialysis
patients.
Measurement of Ca2 pump activity in intact RBCs
Ca2 pump activity was measured with a method recently
described in this laboratory [231. This method measures the
initial rate of Sr2 efflux in Sr2-loaded intact RBCs, where
Sr can substitute for Ca2 translocation by the Ca2 pump (as
Rb can substitute for the K translocation by the Na-K
pump). As previously described, the use of Sr2 allows mea-
surement of Ca2 pump activity under initial rate and steady
state conditions, and it avoids the use of radioactive isotopes
(45Ca2) [detailed in reference 231.
Preparation of erythrocytes
Venous blood from normal controls was collected in hepa-
rinized tubes, and was centrifuged at 1,750 x g for 10 minutes
at 4°C to separate the plasma and the buffy coat, and the
erythrocyte pellet was used immediately. Plasma from controls
or patients was used fresh or frozen at —20°C for incubation
studies.
Cells were loaded with Sr2 by using the calcium ionophore
A-23 187 [24]. Briefly, RBC's were washed twice at 4°C with
isotonic NaC1 and resuspended to a hematocrit of 10% in a
Na-K loading medium containing (in mmol/Iiter): 75 NaC1, 75
KC1, 10 MOPS-TRIS buffer (pH 7,4 at 37°C), 10 glucose and 0.1
MgCl2. SrCI2 (2 mmol/liter) and A-23 187 (final concentration 6
tmoL/1iter), were added to the loading media. RBC's were
incubated for 20 minutes at 37°C under continuous mixing. To
remove the ionophore from membranes, the cells were subse-
quently spun down for five minutes at 4°C and resuspended in
loading media with added bovine serum albumin at a final
concentration of 1 g/liter, and SrCl, (2 mmol!liter). Cells were
incubated at 4°C for 10 minutes, washed, and this procedure
was repeated once, without added SrCI2 Following ionophore
removal, the cells were washed and incubated twice for 10
minutes at room temperature in loading media containing
(mmol!liter): 5 inosine, 2 adenine, 5 Na2HPO4, and 10 MOPS-
TRIS buffer (pH 7.4 at 37°C), 10 glucose and 0.1 MgCl2 to
permit regeneration of intracellular ATP to normal values.
Finally, cells were washed three times in cold loading media,
containing 1 mmol/liter MgCI2.
Sr2-loaded cells (approximately 2 ml) were resuspended in 5
ml of Na-K efflux medium containing (in mmol/liter): 20
NaCl, 130 KCI, 10 MOPS-TRIS buffer (pH 7.4 at 37°C), 1
MgCl2, 10 glucose. This medium was shown in preliminary
studies to maintain a stable cell volume and hemoglobin con-
centration during the efflux step. A portion of the cell suspen-
sion was set aside for measurements of intracellular Sr2
concentration by atomic absorption (IL 457 Atomic Absorption
Spectrophotometer, Instrumentation Laboratory, Wilmington,
Massachusetts, USA), hematocrit, and hemoglobin content by
absorbance at 541 nm.
A total of 21 RBC samples from normal volunteers were used
for these studies. Half a milliliter of the cell suspension was
added to 2 ml of the efflux media, for duplicate measurements of
Sr2 efflux during incubation for 20 minutes at 37°C. In control
experiments we confirmed linearity of Sr2 efflux during this
period. Mean value for Sr2 efflux was 3.41 mmol!liter 'cells!
hr'. Mean internal Sr2 content was 1.89 0.58 mmol/
liter cells (mean SD, N = 15), ranging from 1.1 to 3
mmol!liter cells. Moreover, internal Sr2 content decreased
by about 62% (to 0.75 0.4 mmol/liter cells) during the efflux
period. Internal Ca2 content was very low (1 to 3 mo1/
liter cells) to interfere with Sr2 efflux [23], and remained
constant during the efflux period. After incubation the tubes
were rapidly chilled at 4°C for 2 minutes, centrifuged at 1750 g
for five minutes at 4°C, and the supernatants were transferred
into tubes for Sr2 analysis by atomic absorption spectropho-
tometry.
No evidence of cell lysis was found in control experiments
during incubation in the efflux media. The Sr2 efflux was
calculated according to the following equation:
V = DSr2 + x (100 — Hct)/(Hct x t) (1)
where DSr2 [mmol/(liter cells)] was the increase in external
Sr2 concentration during the incubation time t (hr)', and Hct
was the final hematocrit (%).
Effect of plasma incubation on Ca2 pump activity
The presence of humoral factors that may influence Ca2
pump activity was studied during the efflux step. Control
experiments showed that addition of 10% volume of normal or
uremic plasma-to-efflux medium induced a clear-cut inhibitory
effect on the initial rate of Sr2 efilux. This effect increased
when larger plasma volumes were added, and 20% plasma
incubations were used consistently thereafter. Similarly, a 20%
replacement volume was used during incubation with plasma
ultrafiltrates, as described below.
Validation of atomic absorption spectrophotometry
measurements
Supernatants containing Sr2 were read in duplicate by
atomic absorption spectrophotometry. Plasma or ultrafiltrates
added to the sample could result in analytical interference,
which could include a "matrix" effect, chemical, or ionization
interference. One way to overcome these effects is the use of
the "Standard additions" method, where known amounts are
added to the sample. This makes it possible to make an accurate
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determination of Sr2 concentration in the presence of the
interfering substance. Thus, we validated conventionally made
AA readings by comparison with the more precise "standard
additions" method. For this purpose, each sample was divided
into five fractions, and Sr2 was added to each in increasing
amounts (0, 12.5, 25, 37.5 and 50 tmol/liter), prior to AA
readings. The best fit linear regression was applied to the data
points. Then, the initial amount of Sr2 in each sample was
extrapolated from the X intercept of the standard additions
regression line in the presence of the possible interference, that
is, normal or uremic plasma, and ultrafiltrates.
Preparation of plasma samples and ultrafiltration procedures
Plasma was used fresh or frozen for periods of one to four
weeks before its study. Repeated freezing and thawing was
found in preliminary studies to slightly increase the inhibitory
capacity for the Ca2 pump, and repeated freezing was avoided
subsequently. To assess the approximate molecular size and
obtain preliminary data on the biochemical nature of the inhib-
itory factor(s), plasma from at least three normal or uremic
subjects were ultrafiltered sequentially through low adsorption,
hydrophilic membranes with molecular cutoffs at 100,000,
30,000, 10,000, and 3,000 molecular weight (Centricon 100, 30,
10, 3 microconcentrators, Amicon, Beverly, Maryland, USA).
Sr2-loaded RBCs were then incubated with the ultrafiltrates
(20% volume) for efflux measurements.
In other cases plasma was subjected to heating at 56°Cfor 30
minutes, or boiled at 100°C for 20 minutes. The resultant protein
clot was mechanically disrupted and the sample ultracentri-
fuged at 20,000 x g for one hour, and the supernatant was used
for pump inhibition studies.
Plasma ultrafiltrates were also obtained in vivo from some
patients receiving hemodialysis with cellulose acetate mem-
branes. The clear fluid obtained represents a plasma ultrafiltrate
at a molecular cutoff approximately 6,000 to 8,000 molecular
weight. In some cases, the ultrafiltrates were also subjected to
boiling and the light protein precipitate found after boiling was
removed by centrifugation or filtration through 0.45 m filters.
Finally, we examined the effect of a protease (Sigma P-4630,
bovine pancreatic protease type 1), after incubation with ul-
trafiltrate for one hour at 37°C.
Kinetic analysis of the Ca2 pump
In some cases a kinetic analysis of Sr2 efflux was performed
to determine the effect of different plasmas on the apparent
dissociation constant for internal Sr2 and maximal rate of Sr2
efflux. In this case, SrC12 was added to the loading media at
increasing concentrations, ranging from 0.4 to 2.0 mmol/Iiter.
During effiux measurements RBCs were exposed to control
media or were incubated with either normal or uremic plasma.
For each subject studied, the Sr2 effiux was plotted against the
total internal Sr2 content. Stimulation of the Ca2 pump by
internal Ca2 [22, 24] or internal Sr2 [23] follows a sigmoidal
(S-shaped) saturable function. This curve can be fitted by a two-
Ca2 site model, where only those transport units loaded with
two Ca2 or Sr2 ions are able to translocate ions across the cell
membrane [23, 24]. If p = (1 + K5iSr1) is the probability that
a single site will be occupied by Sr2, then the probability of
two sites being occupied is p2. Therefore, Sr2 efflux (V) as a
function of internal Sr content (Sri) is given by the equations:
V = p2 Vmax = (1 + Ks/Sr1) —2 Vmax (1)
V = Vmax/(l + KsrlSri)2 (2)
where max represented the maximal rate of Sr2 effiux and Kr
was the apparent dissociation constant for internal Sr2.
Equation 2 can be rearranged as follows:
[Sr]j/(V)V2 = Kr/(Vmax)"2 + [Sr]jI(Vma,j"2 (3)
The left member of equation 3, [Sr]I(V)"2 was plotted against
[Sri (Hanes plot, Fig. 5). K5r and Vmax were obtained from the
intercept with the abscissa and the slope, respectively.
Statistical analysis
Data are presented as mean SD. Comparisons between
group means were done by analysis of variance, followed by
Scheffe's test, where applicable. Mean values obtained from the
same patient before and after hemodialysis were compared by
paired t-test. Correlation coefficients and linear regressions
were calculated by standard formulas, using "Stat-View" on a
Macintosh computer. The null hypothesis was rejected when P
<0.05.
Results
General findings
Incubation of Sr2-loaded RBCs with their own plasma or
plasma from normal or uremic subjects inhibited the rate of
Sr2 effiux in all cases. In a typical example, Sr2 efflux
(mmol/liter cells per hr) was 3.86 in the control state, and 2.48
(36% lower) during incubation in normal plasma. Plasma from
uremic patients at the onset of a hemodialysis session inhibited
Sr2 efflux very strongly, decreasing the efilux rate to 1.85
mmol/liter cells per hour, or 52% lower than the control without
plasma and 25% lower than normal plasma. Data for Ca2 pump
inhibition were usually expressed as a percentage of inhibition
over the control efflux medium (% INH/CT), or over the normal
plasma in the same study (% INH/NL).
Validation of AA measurements
Because addition of plasma may have resulted in analytical
interference with AA readings, in a large number of samples the
Sr2 measurements obtained in the usual way were also ana-
lyzed by the "standard additions" method, and values obtained
in both ways were then compared. This procedure validated the
findings of an inhibitory effect of plasma on Sr2 effiux, and
excluded an analytical artifact. Both methods were highly
correlated, and conventional readings were virtually identical
with the extrapolated values read from the "standard addi-
tions" plot (r 0.962, P < 0.001, DF = 76). Thus, a non-
specific "matrix" effect of plasma was not responsible for its
apparent inhibitory effects over the calcium pump.
Evaluation of non-speck/ic inhibitory effects
Control experiments were done to evaluate whether addition
of plasma (containing a number of substances such as NaC1,
Ca2, phosphate, and others) may have a non-specific inhibi-
tory effect on the calcium pump. Effiux medium normally
contained (in mmol/liter) 20 NaCl and 130 KC1. Addition of
and,
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Fig. 1. Inhibitory effect of plasma from normal controls (N 28),
uremic patients with CRF (N = 26), and maintenance hemodialysis
patients (N = 33), on the RBC membrane calcium pump (measured asSr efflux in Sr-1oaded normal RBC's). Degree of inhibition is
expressed as the percentage difference over control values in efflux
solution without plasma (%INH/CT). * Indicates statistical significance
at 95% (Scheffes's test).
plasma at 20% volume proportionally reduced KCI and in-
creased NaC! concentrations, and added Ca2 at approximately
0.25 mmol/liter to the effiux medium. Therefore, at least two
control experiments were done in each case to evaluate the
possible effect of these concentration changes. In these cases
we used the standard addition method for AA readings for a
higher degree of accuracy. Addition of CaCI2 0.25 mmol/liter to
the effiux buffer had no effect on Sr2 efflux (2.97 0.51 vs.
2.93 0.46 mmol/liter cells per hr, with added CaCI2). Simi-
larly, replacement of effiux medium by the loading medium,
containing (in mmol/liter) 75 NaCl and 75 KCI, was without
effect on Sr2 efflux (2.57 0.35 vs. 2.56 0.478 mmol/liter
cells per hr with the replacement medium).
In several experiments, we examined a possible effect of
phosphate on Sr2 efflux. Phosphate was added to the control
buffer prior to the Sr2 efflux step. The following concentra-
tions were used: 0, 2, 4, 6, 8, and 10 mg/dl, which is the range
of values usually found in normal and uremic plasma. Analysis
of variance showed no effect of phosphate on Sr2 efilux at any
of these concentrations (P < 0.676, DF = 5). In addition, there
was no correlation between phosphate additions and Sr2
readings by AA, (r = 0.084, P < 0.677, DF = 26). Therefore,
precipitation of Sr2 with phosphate during the cold centrifuga-
tion step was clearly excluded.
Effect of plasma on Ca2 pump activity
As shown in Figure 1, plasma from 28 normal subjects
inhibited the Ca2 pump by 25 12%. In contrast, incubation
in plasma from 33 hemodialyzed patients, at the start of a
dialysis session, inhibited the pump by 36 18%, (both
expressed as % INH/CT, P < 0.05). These two groups were not
different with respect to sex, however, there was a small
difference in mean age (38 11 vs. 49 17 years) for the
normal and the dialyzed group, respectively (P < 0.05). The age
difference, however, cannot account for the difference in inhib-
itory capacity for the Ca2 pump. First, there was no correla-
tion between age and % INH/CT in this group (Fig. 2), or in
patients with CRF, and when all the subjects were analyzed
together (not shown). Second, a comparison was made in a
subgroup of 28 hemodialyzed patients not different in age from
the normal subjects (38 11 vs. 44 11 years, P = NS), and
the enhanced inhibitory capacity over the Ca2 + pump was well
demonstrated again (% INH/CT = 37 19 in dialyzed vs. 25
12 in the normal group, P < 0.05).
Hemodialysis for four hours resulted in a marked decrease in
the capacity of plasma to inhibit the Ca2 pump (Fig. 3). Thus,
in a group of 15 patients plasma inhibited Ca2 pump activity
much less after acute hemodialysis (16 12 vs. 5 14,
%INH/NL, P < 0.001). In some cases we found as much as a
32% fall in inhibiting capacity after dialysis, and some post-
dialysis plasmas became less inhibitory than normal plasma on
the same study. All values before and after dialysis are illus-
trated in Figure 3.
Plasma ultrafiltrate obtained in vivo during the first few
minutes of a dialysis session (N = 9) was found to be very
inhibitory of the Ca2 pump. Thus, ultrafiltrate inhibited the
pump by 32 9% versus 16 9% (% INH/NL, P < 0.05), when
compared with pre-dialysis plasma in the same session.
A possible relationship between Ca2 pump inhibition and
the blood pressure was evaluated in the hemodialyzed group.
There was no correlation between systolic, diastolic, or mean
blood pressure and the ability of pre-dialysis plasma to inhibit
the Ca2 pump. Similarly, we found no correlation between the
decrease in inhibitory capacity after each hemodialysis and the
fall in blood pressure, the weight change, or the amount of
ultrafiltrate losses during each treatment. These findings are not
surprising, since the patients were nearly normotensive as a
group, and they were all receiving antihypertensive treatment.
The observation was made, however, that patients receiving
calcium influx blockers (N = 9), had the highest values for Ca2
pump inhibition, that is 46 22 versus 30 13 (% INH/CT, P
< 0.02), compared to patients treated with other agents (N =
22). Exclusion of these nine patients, however, did not affect
the statistical significance of the enhanced inhibitory capacity
found in patients versus controls.
Finally, intact 1-84 PTH concentration (mean SD) was 219
216 U, ranging between 6 and 684 U in a large subgroup of
hemodialysis patients (N 22). No correlation was found
between inhibitory capacity (% INH/CT) and the serum PTH
level (r 0.045, P = 0.84).
Correlation with degreeof renal failure
Studies were done in a group of 26 patients with a wide
spectrum of chronic renal insufficiency. In this group, mean
serum creatinine was 228 tmol/liter (range 62 to 916), and mean
age was 57 3 years, not significantly different from the
dialysis group. A strong correlation was observed between
Ca2 pump inhibition by uremic plasma and the serum creati-
nine concentration (Fig. 4; r = 0.75, P < 0.0001). A smaller
inverse correlation was also observed when comparing with
calculated creatinine clearance, based on age and body surface
area (r 0.51, P <0.01).
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Fig. 2. Lack of correlation between RBC
membrane calcium pump inhibition by uremic
plasma (%INHICT) and age (years), in 33
patients receiving hemodialysis.
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Fig. 4. Correlation between plasma inhibitory capacity for the calcium
pump (%IIVH/IVL) and the degree of renal insufficiency, expressed by
the serum creatinine concentration, in 26 patients with CRF. The
strongest inhibition was seen with plasma from patients approaching
end-stage renal disease levels (r = 0.75; P < 0.001).
minutes, and plasma was also ultrafiltered down to a 3,000
molecular weight cutoff. At least three experiments were done
in each case. It was found that the inhibitory capacity remained
present after heating and in the supernatant of boiled plasma;
after one hour incubation in bovine pancreatic protease, and in
the ultrafiltrates smaller than 3,000 molecular weight, demon-
strating that the putative factor(s) is a small molecule, heat-
stable and possibly not a protein or a small peptide. The
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Fig. 3. Decrease in plasma inhibitory capacity against the Ca2 pump
during acute hemodialysis (N - 15). Degree of inhibition is expressed
as the percentage difference over values obtained with normal plasma in
the same study (%INH/NL). In some cases, inhibition decreased after
dialysis to values lower than those with normal plasma (P < 0.001).
Preliminary characterization of the inhibitory flictor
In order to characterize the biochemical nature of the circu-
lating Ca2 pump inhibitor, preliminary studies were done with
both plasma and ultrafiltrate obtained in vivo. Both types of
samples were subjected to heating at 56°C and to boiling for 20
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ultrafiltrates obtained in vivo were slightly different, since
inhibitory activity was present after boiling, though it could be
removed by further centrifugation or filtration. These additional
procedures appeared to remove a precipitate formed during the
boiling step, to which the factor was possibly bound.
Kinetic analysis of pump inhibition
A kinetic analysis was done to determine the relative influ-
ence of plasma factors on the apparent affinity of the Ca2
pump for internal Sr2 (K5r), and the maximal rate of Sr2
translocation (Vmax). Control Kr was 883 .tmol/liter cells, and
max was 7.52 mmollliter cells per hr. K5,. remained unchanged
when Sr2 efflux was measured in presence of normal (848
mol/liter cells) or uremic plasma (941 133 mol/liter cells, N
= 3). In contrast, Vmax was markedly depressed in presence of
normal (3.71 mmol/liter cells per hr), and particularly in uremic
plasma (2.56 0.4 mmol/liter cells per hr, N = 3) in dialysis
patients (Fig. 5).
Discussion
Depressed Ca2-ATPase activity, both basal and in the
calmodulin-activated state, have been reported in RBCs of
uremic patients [14, 251. In one study [25] the Ca2-ATPase
system was unresponsive to stimulation by thyroid hormone,
unlike cells from normal subjects which are known to respond
to this hormone [26]. The present studies were done to search
for a humoral factor in uremic plasma that might influence
membrane calcium transport. In a large group of 59 patients (26
with CRF and 33 on hemodialysis) we found evidence of a
powerful circulating inhibitor of the RBC membrane Ca2
pump. The findings confirm and extend the initial report by
Gafter et a! [141 of a humoral inhibitor of the RBC membrane
Ca2-ATPase in 12 patients. In Gafter's study [14], RBCs were
pre-incubated in a large volume of uremic plasma (300%), and
the activity of the Ca2-ATPase was examined indirectly by
measuring the amounts of phosphate released by RBC mem-
brane ghosts. In contrast, we examined the direct effects of
plasma incubation with intact RBCs. Small plasma volumes (10
to 20%) were sufficient to demonstrate consistent inhibition of
the Ca2 pump by normal and uremic plasma. This factor acts
rapidly, during a 15 to 20 minute incubation period. Plasma
from uremic patients receiving hemodialysis and patients with a
spectrum of renal insufficiency were always found to inhibit the
Ca2 pump very strongly when compared with normal subjects.
These findings demonstrate that defective calcium effiux can be
acquired by normal erythrocytes upon exposure to uremic
plasma. This is similar to earlier observations of humoral
inhibitors of the RBCs Na-K-ATPase in uremia [7, 8, 27].
Recently [27] it was also shown that defective sodium transport
in CRF can be acquired by other cells, such as skeletal muscle,
and that sodium-dependent amino acid transport in adipocytes
closely paralleled diminished sodium pump activity. These
points underline the importance of the acquired transport
defects to abnormal cellular metabolism in uremia. The mech-
anism for these defects is multifactorial and tissue specific [27].
The tissue specificity of the calcium pump inhibitor in uremia
remains to be determined.
Of great interest, Ca2 pump inhibition was directly corre-
lated to the decrease in renal function, expressed either as
plasma creatinine concentration or creatinine clearance. Plasma
from severely uremic patients before the onset of hemodialysis
displayed the strongest degree of Ca2 pump inhibition. These
observations suggest that inhibitory humoral factor(s) may be
retained in proportion to the degree of nephron loss during
progression of renal disease. On the other hand, we have
excluded non-specific effects by normal or uremic plasma, or a
"matrix" effect of plasma during AA measurements. Phos-
phate, in particular, which is retained in uremia, was not
responsible for the findings of calcium pump inhibition, or the
decreased factor's activity after hemodialysis. No correlation
was found between different phosphate levels and Sr2 effiux
inhibition.
Activity of the circulating inhibitor of the calcium pump
markedly decreased during acute hemodialysis. This probably
accounted for the slightly smaller degree of inhibition found in
hemodialyzed patients, compared with CRF cases. On the other
hand there was no apparent correlation between inhibitory
capacity and duration of maintenance hemodialysis. Decrease
in factor activity could be reproduced by in vitro dialysis of
uremic (or normal) plasma, using the same membranes and
dialysate bath as during in vivo treatments. In addition, plasma
ultrafiltrate obtained during the first few minutes of a hemodi-
alysis session was strongly inhibitory and slightly more active
than pre-dialysis plasma obtained from the same patient. This
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Fig. 5. Kinetic analysis o.fSr efflux data.
Hanes plot of the left member of equation 3
([Sr]1/(V)"2), relating Sr2 efflux rate to the
intracellular Sr2 content (see text). K5r and
Vmax were obtained from the intercept with
the abscissa and the slope, respectively. Main
effect of normal, and uremic plasma in
particular, on Sr2 efflux is a marked decrease
in Vmax, with no effect on Sr2 affinity.
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may reflect some concentration of the factor during ultrafiltra-
tion. More importantly, the factor was dialyzable and ultrafil-
trable, suggesting that it was not strongly bound to protein and
was a small molecule (at least smaller than 6,000 to 8,000
molecular wt), the cutoff for the cellulose acetate membranes
most frequently used for dialysis in these patients. Further
insight into the biochemical nature of the factor was obtained by
testing the inhibitory capacity of plasma ultrafiltrates. Filtrates
smaller than 3,000 molecular weight remained inhibitory for the
Ca2 pump. Furthermore, Ca2 pump inhibition was demon-
strated in both plasma and plasma ultrafiltrates after boiling for
20 minutes. In addition, the factor was resistant to incubation in
one type of pancreatic protease. Heat and protease resistance
suggest (but do not exclude) that the circulating factor is not a
protein or a small peptide. The precise nature of the factor must
be determined in future studies. Other investigators have sug-
gested that a circulating inhibitor of the Na-K-ATPase may
be related to oleic and linoleic acids [281. However, recent
experiments using oleic acid demonstrated the special ability of
acidic phospholipids to activate the RBCs Ca2 pump [29;
reviewed in 22]. This makes it unlikely that the inhibitory factor
in our study may be one of the lipids just discussed.
Calcium pump activity was measured in intact RBCs loaded
with Sr2, an alternate substrate for Ca2 translocation by the
calcium pump. The relative slowness of the Sr2 movements
allows the intracellular Sr2 content to remain stable during the
flux experiments. Therefore, the initial rate of Sr2 extrusion
from Sr2-loaded cells can be measured precisely by atomic
absorption. This offers advantages over measurements of RBC
45Ca2 efflux, since very low free Ca2 concentrations are
required to stimulate the pump, and 45Ca2 extrusion is com-
plete within one minute [23]. In addition, kinetic analysis of
Sr2 effiux data was done to examine the mechanism of action
of the plasma inhibitor. Uremic plasma markedly reduced the
maximal rate of Sr2 effiux (Vmax), compared with Vax in the
presence of normal plasma or no added plasma. On the other
hand, there was no change in RBC's affinity for internal Sr2
(Ksr). These data suggest that the plasma inhibitor may reduce:
(I) the turnover rate of cation translocation or (2) the number of
pump units available for Ca2 translocation, as it is the case for
ouabain on the Na pump.
Inhibition of the calcium pump should increase intracellular
free Ca2 concentration. Indeed, high total RBC Ca2 levels in
uremia were found by Gafter et al [14]. This effect may be
widespread, since the membrane calcium pump is present in
most eucaryotic cells [22]. Thus, increased cytosolic Ca2 in
vascular smooth muscle cells may be associated with hyperten-
sion [30, 21]. In our study, however, we could not find a
correlation between blood pressure and plasma inhibitory ac-
tivity for the calcium pump. These groups were not suitable to
establish such a correlation, since many patients were treated
with antihypertensive drugs and were nearly normotensive.
Similarly, we could not establish a correlation with the volume
of ultrafiltrate or weight losses during hemodialysis. Since the
factor can easily be demonstrated in ultrafiltrates through
dialysis membranes, it appears that reduced or absent plasma
inhibitory activity after acute hemodialysis is due to diffusion
losses into the bath, and is not related to plasma volume
changes with each treatment. Finally, two indirect lines of
evidence suggest that the factor found in uremic plasma may be
the same as than in normal subjects, only at a higher concen-
tration. First, inhibition may be reduced by hemodialysis al-
most totally in some cases, to values lower then those in normal
plasma. Second, inhibitory activity decreases in normal plasma
during in vitro dialysis. Identity of these factors, however, must
still be demonstrated.
Endogenous inhibitors of the sodium pump have been found
in hypertension and in patients with renal insufficiency [9—13].
Recently, a ouabain-like compound, that displaces [3H]ouabain
from its receptor, inhibits NaKtATPase and ouabain sensi-
tive 86Rb uptake, has been identified in human plasma [31]. It
was suggested that this circulating factor may modulate intra-
cellular Na and affect intracellular Ca2 and pH homeostasis
in many tissues. Thus, it may be related to the pathogenesis of
hypertension [311. However, this factor is not known to inhibit
the cell membrane Ca2 pump, the effect found in uremic
plasma in our study. This factor has biochemical features
similar to the one described by Kelly et al [13], in that it is a
small molecule, found in boiled or deproteinized plasma. How-
ever, our factor was not lost or adsorbed by ultrafiltration or
dialysis membranes, and its activity in plasma markedly de-
creased after hemodialysis. We found a strong correlation with
the degree of renal insufficiency, and the factor was present
both in CRF and dialyzed patients, while Kelly's factor was
only seen in CRF, and acute dialysis appeared to raise plasma
levels in some of his cases [13]. For all these reasons, it seems
unlikely that our factor may be identical to EDLF, even though
EDLF have been identified in some of the patients enrolled in
our study (data not shown). Finally, parathyroid hormone
levels are increased in many uremic patients, and PTH has been
proposed to increase intracellular Ca2 in RBCs and induce
osmotic fragility [16]. We found no correlation between PTH
plasma concentration and inhibition of the calcium pump by
uremic plasma. Additional studies are required to determine the
biochemical nature of the inhibiting factor and its immunologi-
cal relationship to other substances, such as EDLF.
This may be a newly described inhibitor of the calcium pump,
with biological activity. In fact, known inhibitors such as
vanadate [32] and ruthenium red [33] have no physiological
function, and may be considered experimental tools. Two other
inhibitors were found in the bovine brain [34] and rat liver [351,
but their function and properties remain obscure [22]. In
summary, we found evidence for a circulating inhibitor of the
calcium pump in uremic plasma. This seems to be a dialyzable,
ultrafiltrable substance, smaller than 3,000 molecular weight,
which increases its concentration in CRF in direct correlation
with the degree of renal insufficiency. This substance is likely to
increase intracellular free Ca2 content and thus could be
related to decreased RBC survival in CRF [19—20], and possibly
to cell toxicity and/or hypertension in uremic patients.
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